Immupharma PLC Holding(s) in Company (4170V)
October 28 2014 - 3:00AM
UK Regulatory
TIDMIMM TIDMAV.
RNS Number : 4170V
Immupharma PLC
28 October 2014
28 OCTOBER 2014
ImmuPharma PLC
NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES
Following the Successful GBP3.4m Fund Raising
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
confirm that its long standing shareholder Aviva plc ("Aviva") and
its subsidiaries has notified the Company that it has increased its
shareholding in ImmuPharma Ordinary Shares to 8,143,876
representing a 9.19% shareholding in the Company.
This follows last week's announcement from ImmuPharma that Aviva
was the lead investor in a GBP3.4 million fund raising to support
the pivotal phase III progress of Lupuzor(TM) , the Company's lead
candidate for the treatment of lupus, a potentially life
threatening auto-immune disease.
Commenting on the announcement, Richard Warr, Chairman said: "We
are delighted to have received further endorsement from Aviva for
supporting our plans to take Lupuzor(TM) through its pivotal Phase
III development."
The full TR1 form is shown at the end of this announcement.
For further information please see the Group's web site,
www.immupharma.com, or contact:
+ 44 (0) 20 7152
ImmuPharma plc 4080
Dimitri Dimitriou, Chief
Executive Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Richard Warr, Chairman
Tracy Weimar, Vice President,
Operations and Finance
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7886 2500
Hugh Morgan, Fred Walsh,
Duncan Monteith
For filings with the FCA include
the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
1. Identity of the issuer or Immupharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------------- -----------------------------------------
2. Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------------------------------------------------
Other (please CHANGE TO THE NUMBER OF VOTING RIGHTS
specify): IN ISSUE, FOLLOWING THE RECENT PLACING
------------------------------------------------------------- ---------------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
--------------------------------------------------------------- -------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv) BNY Norwich Union Nominees
Limited 232,080*
Chase (GA Group) Nominees
Limited 6,982,205*
*denotes direct interest
Chase (GA Group) Nominees
Limited 351,098
Chase Nominees Limited 172,211
Vidacos Nominees Limited 406,282
--------------------------------------------------------------- -------------------------------------------
5. Date of the transaction 23 October 2014
and date on
which the threshold is crossed
or
reached: (v)
--------------------------------------------------------------- -------------------------------------------
6. Date on which issuer notified: 24 October 2014
--------------------------------------------------------------- -------------------------------------------
7. Threshold(s) that is/are 4% to 8% change at Direct
crossed or Interest Level
reached: (vi, vii)
--------------------------------------------------------------- -------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
----------------- ----------------------------- ------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
----------------- ---------------- ----------- ------------- ----------------------- --------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
----------------- ---------------- ----------- ------------- ----------- ---------- -------- ----------
Ordinary
Shares
GB0033711010 4,388,986 4,388,986 8,143,876 7,214,285 8.14% 1.05%
---------------- ----------- ------------- ----------- ---------- -------- ----------
929,591
----------------- ---------------- ----------- ------------- ----------- ---------- -------- ----------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ---------------- -------------------------- ----------------------- --------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------- ---------- ------------ ------------- -------------------- ------------------
Nominal Delta
------------------- ---------- ------------ ------------- -------------------- --------- -------
Total (A+B+C)
--------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------- -----------------------------
8,143,876 9.19%
------------------------- -----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
------------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
------------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
---------------------------------------------- ------------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
---------------------------------------------- ------------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
---------------------------------------------- ------------------------------------
13. Additional information: Figures are based the total
number of voting rights of
88,622,463 as per the recent
'Additional Listing' announcement
of 21 October 2014.
---------------------------------------------- ------------------------------------
14. Contact name: Neil Whittaker, Aviva plc
---------------------------------------------- ------------------------------------
15. Contact telephone number: 01603 684420
---------------------------------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLKDLFLZBFLFBF
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
